NarAB Is an ABC-Type Transporter That Confers Resistance to the Polyether Ionophores Narasin, Salinomycin, and Maduramicin, but Not Monensin

Ali-Oddin Naemi1, Hymonti Dey1, Nosheen Kiran1, Sarah Torbergsen Sandvik2, Jannice Schau Slettemeås2, Live L. Nesse2 and Roger Simm1*

1 Institute of Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway, 2 Norwegian Veterinary Institute, Oslo, Norway

Polyether ionophores are antimicrobial compounds used as feed additives in poultry feed to control diseases caused by coccidia. In addition to the anticoccidial activity of these compounds, polyether ionophores also contain antibacterial properties. Resistance to the polyether ionophore narasin was recently shown to exist on mobile plasmids in Enterococcus faecium and the resistance mechanism was suggested to be associated with a two-gene operon encoding an ABC-type transporter. In this study we demonstrate that the genes encoding the putative narasin resistance mechanism confers reduced susceptibility to the polyether ionophores narasin, salinomycin and maduramicin, but not to monensin and suggest that this resistance mechanism should be referred to as NarAB. Importantly, NarAB does not affect the susceptibility of E. faecium to any of the tested antimicrobial compounds that are used in clinical medicine. However, we show that conjugation in the presence of certain polyether ionophores increases the number of vancomycin resistant E. faecium suggesting that narasin and certain other polyether ionophores can contribute to the persistence of VRE in poultry populations.

Keywords: polyether ionophore, narasin, antimicrobial resistance, Enterococcus faecium, VRE

INTRODUCTION

Polyether ionophores are used worldwide as feed additives in conventional rearing of poultry to control coccidiosis caused by the genus Eimeria (Kadykalo et al., 2018). In addition to the anticoccidial activity of polyether ionophores, they also possess antibacterial activity, mainly against Gram-positive bacteria. Until recently, it was assumed that there was no genetically encoded resistance mechanism to polyether ionophores, and that reduced susceptibility of bacteria to these compounds was due to a phenotypic adaptation (Simjee et al., 2012). However, it has been shown that resistance to the polyether ionophore narasin can be transferred between strains of enterococci by conjugation (Nilsson et al., 2012), proving the existence of a genetically encoded narasin resistance mechanism. Evidence has also emerged suggesting that narasin resistance might
be associated with an operon encoding an ABC-type membrane transporter (Nilsson et al., 2016), but this has not yet been directly confirmed experimentally.

The polyether ionophores: monensin, narasin, maduramicin, salinomycin, and lasalocid are approved for use as feed additives in Norway (VKM, 2015). During the last decades, feed supplemented with monensin and narasin have been used for rearing of turkeys and broilers, respectively. In the Norwegian program for surveillance of antimicrobial resistance in the veterinary and food production sectors (NORM-VET), narasin has been included in the test panel for enterococci from different animals and food products. Surveillance data from 2002 to 2018 show that a high proportion of Enterococcus faecium isolates from poultry (25–91%) display reduced susceptibility to narasin (Norm/Norm-Vet, 2001–2014). Interestingly, all available vancomycin resistant E. faecium (VRE) from NORM-VET are also narasin resistant (Norm/Norm-Vet, 2001–2014). Narasin resistant bacteria as such are not considered to be a great problem, since narasin is currently not used in human medicine. However, it is not established if the narasin resistance mechanism offers cross-resistance to medically important antimicrobials. It has also been shown that narasin resistance and vancomycin resistance can be physically linked on transferable plasmids (Sletvold et al., 2008; Nilsson et al., 2016), which indicates that use of narasin can co-select for vancomycin resistance. Vancomycin is used for the treatment of infections caused by Gram-positive bacteria (Alvarez et al., 2016), and is classified by WHO as a critically important antimicrobial for human medicine (WHO, 2017).

Vancomycin resistant E. faecium are a major cause of nosocomial infections worldwide and the incidence of serious infections caused by this opportunistic pathogen increases in many countries (Contreras et al., 2019). In the early 1990s, a community reserve of VRE was discovered in Europe, which raised concern for the public health (van Belkum et al., 1996; Endtz et al., 1997). It is believed it emerged as a result of widespread use of the glycopeptide avoparcin in animal husbandry (Aarestrup, 1995; Klare et al., 1995a,b; Aarestrup et al., 1996; Endtz et al., 1997). It is believed it emerged as a result of widespread use of the glycopeptide avoparcin in animal husbandry (Aarestrup, 1995; Klare et al., 1995a,b; Aarestrup et al., 1996; Endtz et al., 1997). Consequently, avoparcin was banned as a feed additive in Norway and the EU in 1995 and 1997, respectively. For unclear reasons, a VRE reservoir still exists in animal populations in many European countries, more than 20 years after the avoparcin ban. However, the use of polyether ionophores as a feed additive overlapped and/or succeeded the use of avoparcin in poultry feed (Grave et al., 2004; Kaldhusdal et al., 2016). Considering the close association between narasin resistance and vancomycin resistance (Norm/Norm-Vet, 2001–2014; SVARM, 2011, 2013) it is possible that the use of narasin (or other polyether ionophores) in animal husbandry has contributed to maintaining the VRE reservoir in animals in Europe. Due to a decision by the Norwegian broiler industry, broilers have been reared without in-feed anticoccidials since 2016. This may have contributed to a dramatic reduction in narasin resistant isolates in broilers in 2018 (Norm/Norm-Vet, 2019). Turkeys on the other hand, still receive in-feed monensin and the proportion of narasin-resistant E. faecium isolates from turkeys remained on a high level in 2018 (Norm/Norm-Vet, 2019). This suggests that monensin promotes persistence of narasin-resistant E. faecium in turkeys and that the narasin resistance mechanism reduces the bacterial susceptibility to monensin. However, although resistance to monensin has been described in the literature (Newbold et al., 1993; Callaway and Russell, 1999; Houlihan and Russell, 2003), cross-resistance between monensin and narasin has not been detected (Butaye et al., 2000). This study characterizes the ABC-type transporter associated with narasin resistance, and demonstrates that it confers resistance to narasin, salinomycin and maduramicin, but not to monensin or selected antimicrobials currently used in human medicine. In addition, we show that polyether ionophores can influence the outcome of horizontal gene transfer of vancomycin resistance determinants, supporting the notion that they can contribute to spread of vancomycin resistance and persistence of VRE in poultry populations.

**MATERIALS AND METHODS**

**Description of Isolates**

Eighteen E. faecium isolates were selected from the biobank of the Norwegian Veterinary Institute, representing different narasin minimum inhibitory concentration (MIC) values ranging from 1 to 32 mg/L. The 18 isolates were isolated in different years (sampled in 2004, 2006, or 2013) and from different geographical locations. Five of the isolates were also vancomycin-resistant and vanA-positive. The isolates had been susceptibility tested against a panel of antimicrobial compounds as part of the NORM-VET surveillance program (Table 1).

**TABLE 1 | Antimicrobial susceptibility of E. faecium isolates used in this study.**

| Isolate | Van | Nar | Bac | Str | Gen | Tet | Lin | Amp |
|---------|-----|-----|-----|-----|-----|-----|-----|-----|
| WT15    | >128| 8   | 16  | 64  | 4   | 0.5 | 1   | 2   |
| WT1137  | 1   | 8   | 256 | 64  | 16  | 1   | 4   | 2   |
| WT1145  | 2   | 8   | 64  | 64  | 16  | 0.5 | 1   | 1   |
| WT1147  | 1   | 8   | 128 | 32  | 8   | 0.5 | 4   | 2   |
| WT1155  | 1   | 8   | 256 | 32  | 8   | 0.5 | 2   | 2   |
| WT1165  | 1   | 4   | 256 | 64  | 8   | 1   | 4   | 2   |
| WT1174  | 1   | 4   | 256 | 64  | 8   | 1   | 4   | 2   |
| WT1179  | 2   | 8   | 256 | 64  | 8   | 64  | 4   | 0.5 |
| WT1190  | 1   | 1   | 4   | 32  | 16  | 1   | 2   | 1   |
| WT1251  | 2   | 4   | 32  | 256 | 256 | 1   | n.d.| 1   |
| WT1301  | 1   | 8   | 16  | 256 | 256 | 1   | n.d.| <0.25|
| WT1343  | 1   | 8   | 8   | 256 | 256 | 1   | n.d.| 4   |
| WT1366  | 1   | 8   | 2   | 256 | 256 | 1   | n.d.| 2   |
| WT1402  | >128| 16  | 1   | 64  | 8   | 0.5 | 2   | 32  |
| WT2808  | 1   | 1   | 32  | 32  | 8   | 0.5 | 2   | 2   |
| WT4826  | >128| 8   | 4   | 16  | 8   | 0.5 | 0.5 | <0.25|
| WT5252  | >128| 32  | 1   | 64  | 8   | 0.5 | 2   | 0.5 |
| WT5432  | >128| 8   | 1   | 32  | 4   | 0.5 | 1   | 4   |

Van, vancomycin; Nar, narasin; Bac, bacitracin; Str, streptomycin; Gen, gentamicin; Tet, tetracycline; Lin, linezolid; Amp, ampicillin; n.d., not determined.
Detection of the Putative Narasin Resistance Mechanisms

DNA was extracted from the 18 isolates using NUCLISENS easyMAG® (Biomerieux) according to the manufacturer's description. The putative narasin resistance operon was detected using HotStarTaq polymerase (qiagen) in 25 µl PCR reactions containing 1X HotStarTaq Master mix, 0.2 µM of each primer and 2 µl DNA template using primers specific for the two genes (Supplementary Table 3). PCRs were run at 94°C for 15 min, 35 cycles of (94°C, 20 s; 63°C; 30 s; 72°C, 50 s), and 72°C, 10 min.

Conjugation

In general, conjugation was performed by filter mating between a donor strain (the 18 wild type isolates selected from the biobank of the Norwegian Veterinary Institute), and the fusidic acid and donor strain (the 18 wild type isolates selected from the biobank of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusidic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterinary Institute), and the fusic acid and rifampicin resistant plasmid free recipient strain of the Norwegian Veterans
quality and purity of RNA were confirmed by analyzing the samples on a NanoDrop spectrophotometer (Thermo Fisher Scientific) and by running 1 μg of total RNA on a 1% agarose gel. Reverse transcriptase reactions were carried out on 1 μg of RNA using the First strand cDNA synthesis kit (Thermo Scientific) according to the manufacturer’s instructions. The cDNA samples were stored at −20°C until further analysis.

Quantitative PCR

The qPCR reactions were done with a total volume of 20 μL containing 10 μL of 2X PowerUP SYBR Green Mastermix (Applied Biosystems, Thermo Fisher Scientific), cDNA template (0.005 ng/μL) and a final concentration of 2 μM of forward and reverse primers. The qPCR was performed on AriaMX Real-Time PCR system with the following cycling conditions: 1 cycle for 2 min at 50°C (UDG activation), 1 cycle for 2 min at 95°C (Polymerase activation) and 40 cycles of 15 s denaturation at 95°C and 1 min annealing/extension at 60°C. Relative gene expression was determined using the ΔΔCq method with recA, as a reference gene.

Cloning of the Narasin Operon

The operon encoding the putative narasin resistance genes was amplified together with 906 nt of the upstream region from isolates WT1190, WT1402, and WT2608 using primers Nar-Reg-For and Nar-Reg-Rev (Supplementary Table 3). The PCR products and the plasmid pREG45 were digested with FastDigest BamHI and FastDigest Xhol (Thermo Fisher Scientific) and the plasmid and insert were ligated together using rapid DNA ligation kit (Thermo Fisher Scientific). The ligation mixtures were introduced into competent DH5α as described by Chung et al. (1989) and bacteria were plated on LB-agar plates supplemented with spectinomycin (250 mg/L). Single colonies were screened for the presence of the narAB operon by colony PCR using primers: ABC_ATPase_For, ABC_ATPase_Rev, ABCPermease_For, ABCPermease_Rev (Supplementary Table 3) and the integrity of the constructs was confirmed by sanger sequencing at GATC Biotech (Germany), using primers: Nar-seq-rev1, Nar-seq-rev2, Nar-seq-rev3, Nar-seq-rev4, Nar-seq-rev5, Nar-seq-rev6, Nar-seq-for (Supplementary Table 3). The constructs were introduced into the plasmid free E. faecium SE34 (Teng et al., 1998) by electroporation using a previously published protocol (Grady and Hayes, 2003). Briefly, E. faecium SE34 were grown in M17 broth (Oxoid) overnight at 37°C. This culture was diluted 1:100 in 400 ml of M17 broth supplemented with 0.5M sucrose, containing 4% filter-sterilized glycine and grown for 16 h at 37°C. Bacteria were spun down at 4,000 g for 10 min, and the cells were washed once with 20 ml of ice-cold electroporation buffer (0.5M sucrose, 10% glycerol). Aliquotes of electrocompetent cells were stored at −80°C. Plasmid DNA was electroporated into 100 μL of electrocompetent cells using an Gene Pulser electroporation system (Bio-Rad). Electroporation conditions were 2.5 kV, 0.2 cm cuvette gap, 25 μF and 200 ohm. Cells were diluted with 800 μl of Todd–Hewitt broth (Oxoid) supplemented with 0.5M sucrose and incubated at 37°C for 4 h before plating on BHI agar plates supplemented with spectinomycin (200 mg/L).

RESULTS

All 18 isolates selected for this study were shown by PCR to contain the genes encoding the putative narasin resistance mechanism (Supplementary Table 1 and Supplementary Figures 5, 6). The susceptibility data collected as part of the NORM-VET program (Table 1) was supplemented with MIC values of salinomycin, maduramicin, and monensin (Table 2).

In general, it appears that low and high MIC of narasin correlate with low and high MIC, respectively of salinomycin and maduramicin, but not monensin. There was no correlation between low and high MIC of narasin and low and high MIC of any of the other antimicrobial compounds (Table 1). These data indicate potential cross-resistance between narasin, salinomycin and maduramicin, but not between narasin and monensin, vancomycin, bacitracin, streptomycin, gentamicin, tetracycline, linezolid, or ampicillin.

Sequencing of the Operon Encoding the ABC-Type Transporter and the Promoter Region

We hypothesized that the considerable variation in MIC of narasin among the isolates, even though they all were positive for the putative narasin resistance genes, were due to isolate-specific gene-variations. To test this, the relevant genes of a subset of the isolates representing different MIC values were sequenced. Multiple sequence alignment identified three single nucleotide polymorphisms giving rise to amino acid

| Isolate   | Nar* | Sal  | Mad  | Mon  | Las  |
|-----------|------|------|------|------|------|
| WT16      | 8    | 32   | 16   | 8    | 4    |
| WT1137    | 8    | 8    | 32   | 2    | 4    |
| WT1145    | 8    | 8    | 32   | 2    | 4    |
| WT1147    | 8    | 8    | 32   | 2    | 4    |
| WT1155    | 8    | 8    | 32   | 2    | 4    |
| WT1165    | 4    | 16   | 4    | 16   | 4    |
| WT1174    | 4    | 16   | 8    | 16   | 4    |
| WT1179    | 8    | 32   | 16   | 16   | 4    |
| WT1190    | 1    | 2    | 4    | 8    | 8    |
| WT1251    | 8    | 8    | 32   | 2    | 4    |
| WT1301    | 8    | 8    | 32   | 2    | 4    |
| WT1343    | 8    | 8    | 32   | 2    | 4    |
| WT1366    | 8    | 8    | 32   | 2    | 4    |
| WT1402    | 16   | 32   | 32   | 8    | 2    |
| WT2608    | 1    | 1    | 4    | 32   | 1    |
| WT4826    | 4    | 8    | 32   | 8    | 2    |
| WT5252    | 32   | 32   | 8    | 16   | 4    |
| WT5432    | 8    | 32   | 8    | 4    | 4    |

Nar, narasin; Sal, salinomycin; Mad, maduramicin; Mon, monensin; Las, lasalocid.
*The MIC of narasin was also shown in Table 1, but is included here to facilitate comparison.
differences (Supplementary Figures 1–3), but none of them were representative of a certain MIC of narasin. Considering this, we speculated that differences in the promoter region could be responsible for the differences in narasin susceptibility. We attempted to amplify the upstream region of the same subset of isolates, however, we only managed to amplify and sequence the upstream region of three isolates. These three isolates WT1190, WT1402, and WT2608, displayed narasin MIC values of 1, 16, and 1 mg/L, respectively. Isolates WT1190 and WT2608 had identical upstream regions, but the region of these isolates differed compared to isolate WT1402 by 19 nucleotide substitutions and one nucleotide deletion (Supplementary Figure 9), indicating that the differences in narasin MIC might be due to differences in regulation of gene expression.

Conjugation and MIC Testing of Transconjugants

It has previously been shown that narasin resistance can be transferred between strains of *E. faecium* by conjugation. We performed conjugation experiments using the 18 isolates as donors and selected for narasin resistant isolates. Conjugation was successful for 14 of the 18 isolates. Broth microdilution tests confirmed that susceptibility to narasin was decreased 8–16-fold in the transconjugants compared to the recipient strain (Figure 1 and Table 3). The *narA* and *narB* genes were detected in all transconjugants, but not in the recipient strain 64/3 (Supplementary Figures 7, 8 and Supplementary Table 2).

To determine if the narasin resistance mechanism also can confer resistance to other antimicrobial compounds, the susceptibility of the transconjugants was tested against a panel of seven relevant antimicrobials (Table 3). Reduced susceptibility to clinically used antimicrobials was occasionally transferred from the donor strain. Importantly, vancomycin resistance was transferred from two of the five vancomycin resistant isolates. The vanA gene was detected in both transconjugants, but not in the recipient strain 64/3 (Supplementary Figure 9 and Table 3). We also tested the resistance profile of the transconjugants against polyether ionophores (Table 3) and compared it to the corresponding resistance profile of the donor and recipient strains (Figure 1). The resistance profiles of the transconjugants indicate that they are of the recipient background, this was however not confirmed by molecular methods.

Resistance to narasin in the transconjugants correlated with reduced susceptibility to maduramicin, and salinomycin, but not to monensin (Figure 1). It is noteworthy that the MIC of the polyether ionophores varied more in the donors than it did in the transconjugants (Figure 1).

The Operon Encoding the ABC-Type Transporter Is Responsible for Narasin Resistance

To confirm that resistance to narasin was due to the ABC-type membrane transporter, we cloned the operon encoding it together with the native promoter from WT1402 and WT2608 into the vector pREG45, creating constructs pNAR1402 and pNAR2608. Both these constructs conferred reduced susceptibility to narasin compared to the vector control (Table 4). We also tested resistance against vancomycin, salinomycin, maduramicin, and monensin.

This experiment confirmed the previous data that the ABC-type transporter reduces the susceptibility of *E. faecium* against salinomycin and maduramicin, but not to monensin. Interestingly, the increases in MIC of narasin, salinomycin, maduramicin were identical for pNAR1402 and pNAR2608.

TABLE 3 | Antimicrobial resistance of *E. faecium* 64/3 and transconjugants.

| Strain        | Van | Nar | Mon | Mad | Sal | Bac | Str | Gen | Tet | Lin | Amp |
|---------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 64/3          | 0.5 | 0.5 | 5   | 4   | 4   | 16  | 256 | 2   | 4   | 4   | 4   |
| TC15          | 0.5 | 5   | 16  | 8   | >256| 256 | 256 | 4   | 4   | 4   | 4   |
| TC1137        | 0.5 | 5   | 16  | 8   | >256| 256 | 256 | 4   | 4   | 4   | 4   |
| TC1145        | 0.5 | 5   | 16  | 8   | 256 | 256 | 256 | 4   | 4   | 4   | 4   |
| TC1147        | 0.5 | 5   | 16  | 8   | 256 | 256 | 256 | 4   | 4   | 4   | 4   |
| TC1165        | 0.5 | 5   | 32  | 8   | >256| 512 | 4   | 4   | 4   | 4   | 4   |
| TC1174        | 0.5 | 5   | 16  | 8   | >256| 256 | 256 | 4   | 4   | 4   | 4   |
| TC1179        | 0.5 | 5   | 16  | 8   | >256| 256 | 256 | 4   | 4   | 4   | 4   |
| TC1190        | 0.5 | 5   | 16  | 8   | >256| 256 | 256 | 16  | 4   | 4   | 4   |
| TC1402        | 256 | 8   | 32  | 8   | 16  | 256 | 256 | 4   | 4   | 4   | 4   |
| TC2608        | 0.5 | 5   | 16  | 8   | 64  | 256 | 256 | 2   | 4   | 4   | 4   |
| TC4826        | 0.5 | 5   | 16  | 8   | 16  | 256 | 256 | 2   | 4   | 4   | 4   |
| TC5252        | 256 | 8   | 32  | 8   | 16  | 512 | 4   | 4   | 4   | 4   |
| TC5432        | 0.5 | 5   | 16  | 4   | 512 | >256| 4   | 4   | 2   | 4   | 4   |
| Van, vancomycin; Nar, narasin; Mon, monensin; Mad, maduramicin; Sal, salinomycin; Bac, bacitracin; Str, streptomycin; Gen, gentamicin; Tet, tetracycline; Lin, lincomycin; Amp, ampicillin. *vanA* positive isolate. Strain 64/3 is the recipient. TC, transconjugant; the number corresponds to the wild type donor number.
TABLE 4 | Susceptibility to polyether ionophores and vancomycin.

| Strain                  | Antimicrobial compound (mg/L) |
|-------------------------|-------------------------------|
|                         | Van  | Nar  | Mon  | Sal  | Mad  |
| SE34 (p REG45)          | 0.5  | 2    | 20   | 8    | 32   |
| SE34 (pNAR1402)*        | 0.5  | 16   | 20   | 64   | 256  |
| SE34 (pNAR2608)*        | 0.5  | 16   | 20   | 64   | 256  |

Van, vancomycin; Nar, narasin; Mon, monensin; Sal, salinomycin; Mad, maduramicin. *The upstream region of these constructs differ by 20 single nucleotide polymorphisms.

Narasin Induces the Expression of the Narasin Resistance Operon

It is possible that narasin induces expression of the narasin resistance mechanism. To test this, we performed RT-qPCR analysis of *E. faecium* before and after exposure to narasin (Figure 2). Transcription of the narasin resistance genes increased slightly during exponential growth in the absence of narasin. However, addition of narasin induced expression in WT1190, WT1402, and WT2608 (Figure 2A) as well as in Tc2608 and Tc1402 (Figure 2B).

Certain Polyether Ionophores Stimulate the Number of Vancomycin Resistant Transconjugants

Since vancomycin resistance and narasin resistance can transfer simultaneously between strains of *E. faecium* (Nilsson et al., 2012; Table 3), we tested if polyether ionophores influence the occurrence of vancomycin-resistant transconjugants. For this purpose, we performed conjugation experiments between a vancomycin-resistant and narasin-resistant donor (WT1402) and a susceptible recipient (64/3) and analyzed the number of vancomycin-resistant transconjugants. The conjugation experiment was performed in the presence of different concentrations of narasin ranging from 0.25 to 8 mg/L and compared with control conditions without narasin. For comparison, the MIC value of narasin for the recipient was of 0.5 mg/L and the donor and transconjugant had MIC values of 16 and 8 mg/L, respectively (Tables 1, 2). The occurrence of vancomycin-resistant transconjugants varied in a narasin concentration dependent fashion (Figure 3).

These results prompted a conjugation experiment to test the effect of other polyether ionophores on occurrence of vancomycin-resistant transconjugants. The occurrence of vancomycin resistant transconjugants significantly increased in the presence of maduramicin, and salinomycin, but not monensin (Figure 4).

DISCUSSION

Narasin resistance has been associated with a region on large transferrable plasmids encoding an uncharacterized ABC-type membrane transporter (Nilsson et al., 2016). In this study, we performed the first detailed characterization of this putative efflux pump and show that expression of the operon encoding it is induced by narasin, and that these genes are sufficient for achieving reduced susceptibility to narasin. We therefore suggest that the ATPase and permease subunits should be referred to as NarA and NarB, respectively and that the narasin resistance mechanism should be designated NarAB.

Previous publications report attempts to characterize polyether ionophore resistance mechanisms. The narAB operon occurs on pVEF3 (Nilsson et al., 2016), a sequenced and partially characterized plasmid from an *E. faecium* strain isolated from poultry in Norway (Sletvold et al., 2008). Sletvold et al. (2008) cloned a putative ABC-type transporter encoded by an operon...
Monensin resistance can develop in bacteria upon exposure to the corresponding amino acid sequences did not reveal essential differences that could explain the observed differences in narasin susceptibility. Analyses of the upstream regions of narAB from three isolates revealed 20 nucleotide differences that could affect transcription of narAB. In line with this, our transcriptional analysis displayed a trend of higher transcription of narAB in the WT1402 compared to WT1190 and WT2608 and in Tc1402 compared to Tc2608, however, the difference in expression was not statistically significant (Student's t-test; p > 0.05). We observed a twofold difference in MIC of narasin between Tc1402 and Tc2608. Based on these results, we cannot rule out that differences in the upstream region of narAB affects expression of the resistance mechanism. The difference in MIC of narasin between WT1402 and WT2608 is bigger than the difference in narasin MIC between Tc1402 and Tc2608 suggesting that not only the promoter region, but also the genetic background of the E. faecium strains affect the narasin susceptibility. Interestingly, when the narAB operons of WT1402 and WT2608 were cloned together with the upstream regions into pREG45, the constructs conferred identical narasin susceptibility of SE34. This may indicate that unknown factors on the respective wild type plasmids encoding narAB can influence the susceptibility to narasin.

It has previously been suggested that narasin resistance could be linked with resistance to medically important antimicrobials (Norm/Norm-Vet, 2001–2014; Nilsson et al., 2012, 2016), and a physical linkage between narasin resistance and vancomycin resistance has been demonstrated (Sletvold et al., 2008; Nilsson et al., 2016). In addition, a statistically significant correlation between narasin resistance and bacitracin resistance has been reported (VKM, 2015). However, we clearly show that NarAB does not directly confer resistance to any of the tested clinically used antimicrobials. This indicates that observed epidemiological association between narasin resistance and resistance to clinically used antimicrobials is likely due to co-occurrence of multiple resistance mechanisms in the same isolate. On the other hand, NarAB confer increased tolerance to salinomycin and maduramicin, demonstrating that the resistance mechanism is not specific for narasin. Cross-resistance between narasin and salinomycin has previously been shown in E. faecium isolates from farm animals (Butaye et al., 2000, 2001). Remarkably, NarAB does not affect the susceptibility of E. faecium (SE34) to monensin. This is interesting since surveillance data from NORM-VET demonstrated high prevalence of narasin resistant E. faecium in the Norwegian turkey population that receive monensin, but not narasin as a feed additive (Norm/Norm-Vet, 2019). In addition, we have previously shown that broiler feed, free of antimicrobial compounds significantly reduces the narasin-resistant population of E. faecium compared to narasin feed, free of antimicrobial compounds significantly reduces the narasin-resistant population of E. faecium compared to narasin

located between nucleotides 4658 and 6675 on pVEF3. The authors did not detect activity conferring resistance to any of the 27 tested antimicrobial compounds by this construct in E. faecium. However, the narAB operon of pVEF3 is located between 37290 and 39808 (Sletvold et al., 2008; Nilsson et al., 2016), and this operon was never characterized. A resistance mechanism against a polyether ionophore was identified in 1994 when a genomic library of Streptomyces lividans 1994 was screened for the tetransin resistance determinant (Linton et al., 1994). This screen identified an operon containing the genes trnB2 and trnB3, encoding an ABC-type membrane transporter that might be involved in self-resistance in the tetransin producing bacterium. The tetransin resistance mechanism has not been further characterized. Monensin resistance can develop in bacteria upon exposure to the antimicrobial compound (Newbold et al., 1993; Callaway and Russell, 1999; Houlihan and Russell, 2003). Monensin resistance has been attributed to thickening of the cell envelope and appears to be reversible when bacteria are growing in the absence of monensin. So far, monensin resistance has not been linked to a genetic determinant.

The E. faecium isolates included in this study are all positive for the narAB operon, but display different susceptibility to narasin. Analyses of the DNA sequences of narA and narB and the corresponding amino acid sequences did not reveal essential differences that could explain the observed differences in narasin susceptibility. Analyses of the upstream regions of narAB from three isolates revealed 20 nucleotide differences that could affect transcription of narAB. In line with this, our transcriptional analysis displayed a trend of higher transcription of narAB in the WT1402 compared to WT1190 and WT2608 and in Tc1402 compared to Tc2608, however, the difference in expression was not statistically significant (Student's t-test; p > 0.05). We observed a twofold difference in MIC of narasin between Tc1402 and Tc2608. Based on these results, we cannot rule out that differences in the upstream region

![FIGURE 3](image-url) Narasin increases the number of vancomycin-resistant transconjugants. Filter mating was performed overnight, in the presence and absence of different concentrations of narasin. Ten-fold serial dilutions of bacteria were plated on BHI-agar supplemented or not with vancomycin (4 mg/L). The ratio of vancomycin-resistant and susceptible colony forming units (CFU) was calculated. Shown are average values and 95% confidence intervals of at least five independent experiments.

![FIGURE 4](image-url) Monensin does not increase the number of vancomycin-resistant transconjugants. Filter mating was performed overnight, in the presence and absence of narasin, maduramicin, salinomycin, and monensin. Ten-fold serial dilutions of bacteria were plated on BHI-agar supplemented or not with vancomycin (4 mg/L). The ratio of vancomycin-resistant and susceptible CFU was calculated. Average values and 95% confidence intervals from at least five independent experiments are shown.

---

**Frontiers in Microbiology**

**Naemi et al.**

---

**NarAB Confers Polyether Ionophore Resistance**

---

**February 2020 | Volume 11 | Article 104**

---

**Naemi et al. NarAB Confers Polyether Ionophore Resistance**

---

**Frontiers in Microbiology | www.frontiersin.org**

---

**February 2020 | Volume 11 | Article 104**

---

**Naemi et al. NarAB Confers Polyether Ionophore Resistance**

---

**Frontiers in Microbiology | www.frontiersin.org**

---

**February 2020 | Volume 11 | Article 104**

---

**Naemi et al. NarAB Confers Polyether Ionophore Resistance**

---

**Frontiers in Microbiology | www.frontiersin.org**

---

**February 2020 | Volume 11 | Article 104**
containing feed (Simm et al., 2019). This raises the question why narasin-resistant variants constitute a large proportion of the \textit{E. faecium} population in turkeys, since there does not seem to be an obvious selection pressure.

We showed in a previous study that all VRE available in the biobank of the Norwegian Veterinary Institute are also resistant to narasin (Simm et al., 2019). It has also been shown that the resistance mechanisms to narasin and vancomycin can exist on the same plasmids and can be co-transferred between \textit{E. faecium} strains (Sletvold et al., 2008; Nilsson et al., 2012, 2016). We show that in two of five cases, narasin resistance and vancomycin resistance co-existed in the transconjugants following conjugation between a vancomycin and narasin resistant donor and a vancomycin and narasin susceptible recipient. The resistance profiles of the transconjugants indicate that vancomycin and narasin resistance were co-transferred from VRE isolates to a plasmid-free \textit{E. faecium} strain (Table 3). However, the recipient background of the transconjugants was not confirmed by molecular methods, which is a weakness of the experiment. Nonetheless, the experiment supports the previous findings that vancomycin and narasin resistance determinants occasionally co-exist on transferrable plasmids (Nilsson et al., 2012), and strengthen the hypothesis that narasin can promote persistence of vancomycin resistance in the \textit{E. faecium} population (Simm et al., 2019). To further corroborate this notion narasin stimulated the occurrence of vancomycin resistant transconjugants in a concentration dependent manner (Figure 3). Interestingly, this was also the case for salinomycin and maduramicin, but not monensin, indicating that the resistance mechanism NarAB supports horizontal gene transfer under relevant selection pressure. Thereby, the use of in-feed narasin, salinomycin, and maduramicin may not only promote persistence of VRE in the \textit{E. faecium} population of animals, but also promote dissemination of vancomycin resistance in the gut-microbiota of animals. Considering this, the justification for the widespread use of polyether ionophores as additives in animal feed should be re-evaluated.

**DATA AVAILABILITY STATEMENT**

The datasets generated for this study can be found in the NCBI, accession numbers: MN590304–MN590310.

**AUTHOR CONTRIBUTIONS**

RS conceived and designed the work. A-ON, HD, NK, SS, JS, and RS contributed to the acquisition of data. A-ON, HD, NK, SS, JS, LN, and RS contributed to the analysis and interpretation of data. RS wrote the first draft of the manuscript. A-ON, HD, JS, LN, and RS wrote sections of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.

**FUNDING**

This work was supported by the Research Council of Norway (250212/E50).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2020.00104/full#supplementary-material

**REFERENCES**

Aarestrup, F. M. (1995). Occurrence of glycopeptide resistance among \textit{Enterococcus faecium} isolates from conventional and ecological poultry farms. \textit{Microb. Drug Resist.} 1, 255–257. doi: 10.1089/mdr.1995.1.255

Aarestrup, F. M., Kruse, H., Tast, E., Hammerum, A. M., and Jensen, L. B. (2000). Associations between the use of antimicrobial agents for growth promotion and the occurrence of resistance among \textit{Enterococcus faecium} from broilers and pigs in Denmark. \textit{Finland, and Norway. Microb. Drug Resist.} 6, 63–70. doi: 10.1089/mdr.2000.6.63

Alvarez, R., Lopez Cortes, L. E., Molina, J., Cisneros, J. M., and Pachon, J. (2016). Optimizing the clinical Use of vancomycin. \textit{Antimicrob. Agents Chemother.} 60, 2601–2609. doi: 10.1128/AAC.03147-15

Bender, J. K., Fiedler, S., Klare, I., and Werner, G. (2015). Complete genome sequence of the gut commensal and laboratory strain \textit{Enterococcus faecium} 64/3. \textit{Genome Announc} 3:e01275-15. doi: 10.1128/genomeA.01275-1215

Butaye, P., Devrieze, L. A., and Haesebrouck, F. (2000). Incomplete cross resistance against ionophores in \textit{Enterococcus faecium} and \textit{Enterococcus faecalis} strains from pigs and poultry. \textit{Microb. Drug Resist.} 6, 59–61. doi: 10.1089/mdr.200.0.6.59

Butaye, P., Devrieze, L. A., and Haesebrouck, F. (2001). Differences in antibiotic resistance patterns of \textit{Enterococcus faecalis} and \textit{Enterococcus faecium} strains isolated from farm and pet animals. \textit{Antimicrob. Agents Chemother.} 45, 1374–1378. doi: 10.1128/AAC.45.5.1374-1378.2001

Callaway, T. R., and Russell, J. B. (1999). Selection of a highly monensin-resistant \textit{Prevotella bryantii} subpopulation with altered outer membrane characteristics. \textit{Appl. Environ. Microbiol.} 65, 4753–4759. doi: 10.1128/ae.65.11.4753-4759.1999

Chung, C. T., Niemela, S. L., and Miller, R. H. (1989). One-step preparation of competent \textit{Escherichia coli}: transformation and storage of bacterial cells in the same solution. \textit{Proc. Natl. Acad. Sci. U.S.A.} 86, 2172–2175. doi: 10.1073/pnas.86.7.2172

Contreras, G. A., Munita, J. M., and Arias, C. A. (2019). Novel strategies for the management of vancomycin-resistant enterococcal infections. \textit{Curr Infect Dis Rep} 21, 22. doi: 10.1007/s11908-019-0680-y

Endtz, H. P., van den Braak, N., van Belkum, A., Kluymans, J. A., Koelman, J. G., Spanjaard, L., et al. (1997). Fecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in The Netherlands. \textit{J. Clin. Microbiol.} 35, 3026–3031. doi: 10.1128/jcm.35.12.3026-3031.1997

Grady, R., and Hayes, F. (2003). Axe-Txe, a broad-spectrum proteic toxin-antitoxin system specified by a multidrug-resistant, clinical isolate of \textit{Enterococcus faecium}. \textit{Mol. Microbiol.} 47, 1419–1432. doi: 10.1046/j.1365-2958.2003.03387.x

Grave, K., Kaldhusdal, M. C., Kruse, H., Harr, L. M., and Flatlandsmo, K. (2004). \textit{Enterococcus faecalis} strain \textit{E. faecalis} subpopulation with altered outer membrane characteristics. \textit{Appl. Environ. Microbiol.} 65, 4753–4759. doi: 10.1128/ae.65.11.4753-4759.1999

Houlihan, A. J., and Russell, J. B. (2003). The susceptibility of ionophore-resistant \textit{Clostridium difficile} to other antibiotics. \textit{J Antimicrob Chemother} 52, 623–628. doi: 10.1093/jac/dkg398
Kadykalo, S., Roberts, T., Thompson, M., Wilson, J., Lang, M., and Espesee, O. (2018). The value of anticoccidials for sustainable global poultry production. Int. J. Antimicrob. Agents 51, 304–310. doi: 10.1016/j.ijantimicag.2017.09.004

Kalduhsudal, M., Benestad, S. L., and Lovland, A. (2016). Epidemiologic aspects of necrotic enteritis in broiler chickens - disease occurrence and production performance. Avian. Pathol. 45, 271–274. doi: 10.1080/03079457.2016.1163521

Klare, I., Heier, H., Claus, H., Bohme, G., Marin, S., Seltmann, G., et al. (1995a). Enterococcus faecium strains with vanA-mediated high-level glycopeptide resistance isolated from animal foodstuffs and fecal samples of humans in the community. Microb. Drug Resist. 1, 265–272. doi: 10.1089/mdr.1995.1.265

Klare, I., Heier, H., Claus, H., Reissbrodt, R., and Witte, W. (1995b). vanA-mediated high-level glycopeptide resistance in Enterococcus faecium from animal husbandry. FEMS Microbiol. Lett. 125, 165–171. doi: 10.1111/j.1574-6968.1995.tb07353.x

Linton, K. J., Cooper, H. N., Hunter, I. S., and Leadlay, P. F. (1994). An ABC-transporter from Streptomyces longisporoflavus confers resistance to the polyether-ionophore antibiotic tetronasin. Mol. Microbiol. 11, 777–785. doi: 10.1111/j.1365-2958.1994.tb00355.x

Madeira, F., Park, Y. M., Lee, J., Buso, N., Gur, T., Madhusoodanan, N., et al. (2019). The EMBL-EBI search and sequence analysis tools APIs in 2019. Mutat. Res. 84, 80–83. doi: 10.1016/j.plasmid.2008.04.002

SVARM, (2011). “SVARM 2010, swedish veterinary antimicrobial resistance monitoring,” in The National Veterinary Institute (SVA), (Uppsala).

SVARM, (2013). “SVARM 2012, swedish veterinary antimicrobial resistance monitoring,” in The National Veterinary Institute (SVA), (Uppsala).

Nilsson, O., Greko, C., Bengtsson, B., and Englund, S. (2012). Genetic diversity among VRE isolates from Swedish broilers with the coincidental finding of transferrable decreased susceptibility to narasin. J. Appl. Microbiol. 112, 716–722. doi: 10.1111/j.1365-2672.2012.05254.x

Nilsson, O., Myrenas, M., and Agren, J. (2016). Transferable genes putatively conferring elevated minimum inhibitory concentrations of narasin in Enterococcus faecium from Swedish broilers. Vet Microbiol 184, 80–83. doi: 10.1016/j.vetmic.2016.01.012

Norm/Norm-Vet (2001-2014). NORM/NORM-VET 2000-2014, in Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway, (Tromsø).

Norm/Norm-Vet, (2019). “Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway,” in NORM/NORM-VET 2018, (Tromsø). Simjee, S., Heffron, A. L., Pridmore, A., and Shryock, T. R. (2012). Reversible monensin adaptation in Enterococcus faecium, Enterococcus faecalis and Clostridium perfringens of cattle origin: potential impact on human food safety. J. Antimicrob. Chemother 67, 2388–2395. doi: 10.1093/jac/dks236

Simm, R., Slettemeas, J. S., Norstrom, M., Dean, K. R., Kalduhsudal, M., and Urdahl, A. M. (2019). Significant reduction of vancomycin resistant E. faecium in the Norwegian broiler population coincided with measures taken by the broiler industry to reduce antimicrobial resistant bacteria. PLoS One 14:e0226101. doi: 10.1371/journal.pone.0226101

Sletvold, H., Johnsen, P. J., Hamre, I., Simonsen, G. S., Sundsfjord, A., and Nielsen, K. M. (2008). Complete sequence of Enterococcus faecium pVEF3 and the detection of an omega-epsilon-zeta toxin-antitoxin module and an ABC transporter. Plasmid 60, 75–85. doi: 10.1016/j.plasmid.2008.04.002

WHO, (2017). The risk of development of antimicrobial resistance with the use of coccidiostats in poultry diets, “ in Opinion of the the Panel on Animal Feed of the Norwegian Scientific Committee for Food Safety, (Oslo).

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.